Background Therapeutic cancer vaccines have shown activity in metastatic castration-resistant
prostate cancer (mCRPC), and methods are being assessed to enhance their efficacy. …

Purpose: M7824 (MSB0011359C) is an innovative first-in-class bifunctional fusion protein
composed of a mAb against programmed death ligand 1 (PD-L1) fused to a TGFβ “trap.” …

A concurrent multicenter, randomized Phase II trial employing a recombinant poxviral vaccine
provided evidence of enhanced median overall survival (OS) (p = 0.0061) in patients with …

Background Avelumab (MSB0010718C) is a human IgG1 monoclonal antibody that binds to
PD-L1, inhibiting its binding to PD-1, which inactivates T cells. We aimed to establish the …

Purpose: In solid tumors such as prostate cancer, novel paradigms are needed to assess
therapeutic efficacy. We utilized a method estimating tumor growth and regression rate …

Prostvac is a prostate cancer vaccine regimen consisting of a recombinant vaccinia vector as
a primary vaccination, followed by multiple booster vaccinations employing a recombinant …

Background Checkpoint inhibitors have not been effective for prostate cancer as single
agents. Durvalumab is a human IgG1-K monoclonal antibody that targets programmed death …

In the last few years, immunotherapy has become an important cancer treatment modality,
and although the principles of immunotherapy have evolved over many decades, the FDA …

Immunotherapy is an important breakthrough in cancer. US Food and Drug Administration-approved
immunotherapies for cancer treatment (including, but not limited to, sipuleucel-T, …

Background HuMax-IL8 (now known as BMS-986253) is a novel, fully human monoclonal
antibody that inhibits interleukin-8 (IL-8), a chemokine that promotes tumor progression, …